Daewoong pharmaceutical, announces Nuceiva™ Approval by Evolus in Europe

Daewoong pharmaceutical, announces Nuceiva™ Approval by Evolus in Europe - Evolus, the exclusive partner of Daewoong pharmaceutical, received marketing authorization for Nuceiva from European Commission (EC) for glabellar line indication - Daewoong pharmaceutical, became the 1st Korean Botulinum toxin manufacturer entering both US and EU market - Expecting Nuceiva launch in Europe in 2020, in Canada in the fourth quarter The Botulinum toxin product manufactured by Daewoong pharmaceutical enters European market, which is the 2nd largest market of Botulinum toxin next to US market. Daewoong pharmaceutical announced Evolus, the exclusive partner of Daewoong pharmaceutical, received market approval for Nuceiva from European Commission (EC) on 1st Oct. EC granted approval of Nuceiva for the glabellar line indication, and Evolus would be able to market Nuceiva in 31 countries including all 28 European Union member states plus Iceland, Norway and Liechtenstein. EC approval of Nuceiva is a big achievement for Daewoong, in the view of entering both US and Europe market which is the biggest market possessing 70% of global Botulinum market. Evolus holds the marketing right of Nuceiva in Europe, and expects to launch Nuceiva in Europe in next 2020. Seongsoo Park, Head of Nabota Business division said, “EC approval, followed by US FDA approval, demonstrates the high quality and efficacy of Daewoong manufactured Botulinum toxin products”, “By entering the largest neurotoxin market, Europe and US, we will demonstrate the excellence of Daewoong manufactured Botulinum toxin product globally, and contribute to enhance the prestige of Korean Pharmaceutical companies in global. The product was approved by the US FDA in February 2019, for the 1st Korean manufactured Botulinum toxin product, and launched under the brand name, Jeuveau®, in May 2019.  Nuceiva™ was approved by Health Canada in August 2018 and expected Nuceiva™ to launch in Canada in the fourth quarter. #   #   #

The release as fetched from its publisher. daewoong.co.kr ↗